Nanoparticles to help guide prostate cancer surgery
Part of Cancer, Kidney & urinary clinical trials.
This Phase 1 study tests nanoparticles (tiny particles) that are meant to help surgeons better find and remove prostate cancer tissue during surgery. You may be offered standard prostate surgery plus imaging with a study tracer to guide the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You are scheduled for standard-of-care prostate surgery: either primary prostate removal with pelvic lymph node dissection, or salvage pelvic lymph node dissection
- For primary surgery, you have higher-risk prostate cancer (stage T3a or higher, or Gleason score 8–10, or PSA above 20)
- For salvage surgery, imaging shows a suspicious pelvic lymph node (on CT/MRI or PSMA PET)
- You can safely have MRI and a PET/scan (no serious scanner limitations like certain implants or severe claustrophobia)
- You must be able to lie still in the scanner for about 30 minutes and fit within the scanner weight limit
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special prostate scan called PSMA PET/CT can help doctors decide which pelvic lymph nodes to remove during prostate surgery. It may improve who needs lymph node surgery by using scan results to guide the operation.
This trial uses a special scan (PSMA-PET) to find where prostate cancer has returned after surgery. Then doctors give a lower dose of radiation only to that area, which may reduce side effects. It is for men whose PSA level is rising after prostate removal.
This trial is testing whether a special scan (PSMA PET/CT) before surgery can help doctors decide if you need to remove lymph nodes. It is for men with high-risk prostate cancer who are already planning to have robot-assisted prostate removal.
This trial tests if a special PET scan using PSMA-1007 can find prostate cancer spread in men who have just been diagnosed with high-risk prostate cancer and plan to have surgery. The scan may help doctors better understand the cancer before removing the prostate and lymph nodes.
This trial studies whether operating on a small, one-sided (unilateral) area of prostate cancer spread in the pelvic lymph nodes—found on a PSMA PET scan—can help control recurrence. It’s meant for people whose PSA is still low and whose spread appears limited on the scan.
This trial compares two radioactive drugs (177Lu-PSMA-617 and 225Ac-PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that has not spread far. The goal is to see which drug is better at shrinking the tumor and reducing the chance of cancer coming back.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.